Cell Therapeutics (CTIC -2.6%) dips after the FDA sets a goal date of April 2012 for a decision...

|About: CTI BioPharma Corp. (CTIC)|By:, SA News Editor

Cell Therapeutics (CTIC -2.6%) dips after the FDA sets a goal date of April 2012 for a decision on its New Drug Application of pixantrone, a treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma that the company resubmitted in October 2011. The drug is also under evaluation by regulators in Europe, and the Committee for Human Medicinal Products is set to release its decision in January 2012.